Tretinoin
- Generic Name
- Tretinoin
- Brand Names
- Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 302-79-4
- Unique Ingredient Identifier
- 5688UTC01R
- Background
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...
- Indication
Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...
- Associated Conditions
- Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin
- Associated Therapies
- -
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-08-04
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 151
- Registration Number
- NCT01409161
- Locations
- 🇺🇸
MD Anderson Regional Care Center-Bay Area, Nassau Bay, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Regional Care Center-Katy, Houston, Texas, United States
A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Galderma Brasil Ltda.
- Target Recruit Count
- 128
- Registration Number
- NCT01406080
- Locations
- 🇧🇷
Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Paraná, Brazil
🇧🇷Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil
🇧🇷Centro de Dermatologia Dona Libania, Fortaleza, Ceará, Brazil
Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT01349556
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 24
- Registration Number
- NCT01283464
- Locations
- 🇺🇸
Johns Hopkins Dept. of Dermatology, Baltimore, Maryland, United States
Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
- Conditions
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Registration Number
- NCT01275274
- Locations
- 🇺🇸
UNC Kidney Center, Chapel Hill, North Carolina, United States
Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Spear Pharmaceuticals
- Target Recruit Count
- 958
- Registration Number
- NCT01243450
- Locations
- 🇺🇸
Cu-Tech, LLC, Mountain Lakes, New Jersey, United States
Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2017-01-26
- Target Recruit Count
- 300
- Registration Number
- NCT01226303
- Locations
- 🇮🇹
Dipartimento di Biotecnologie Cellulari ed Ematologia, Roma, Italy
Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 107
- Registration Number
- NCT01048645
- Locations
- 🇲🇽
National Institute of Cancerología, Mexico City, Mexico
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
- Conditions
- Interventions
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- University of Iowa
- Registration Number
- NCT01048086
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker
- First Posted Date
- 2010-01-01
- Last Posted Date
- 2010-01-01
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 230
- Registration Number
- NCT01041833
- Locations
- 🇲🇽
Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.